James Dodge
James Dodge, Orland Park, IL US
Patent application number | Description | Published |
---|---|---|
20100287029 | METHODS AND APPARATUS TO DETERMINE EFFECTS OF PROMOTIONAL ACTIVITY ON SALES - Example systems, methods, processes, and apparatus for determining expected base sales for a product include obtaining sales data for a product sold at a point of sale location. The sales data can be organized in a time series according to a predetermined time period. The method further includes identifying a promotional event for at least one of the product and the point of sale location and excluding sales data corresponding to the promotional event. The remaining sales data is processed using a smoothed moving average model involving a plurality of passes through the remaining sales data. Expected base data for the product is generated based on the smoothed moving average model and output to a user. | 11-11-2010 |
20120303414 | METHODS AND APPARATUS TO DETERMINE EFFECTS OF PROMOTIONAL ACTIVITY ON SALES - Example systems, methods, processes, and apparatus for determining expected base sales for a product include obtaining sales data for a product sold at a point of sale location. The sales data can be organized in a time series according to a predetermined time period. The method further includes identifying a promotional event for at least one of the product and the point of sale location and excluding sales data corresponding to the promotional event. The remaining sales data is processed using a smoothed moving average model involving a plurality of passes through the remaining sales data. Expected base data for the product is generated based on the smoothed moving average model and output to a user. | 11-29-2012 |
James Dodge, Shrewsbury, MA US
Patent application number | Description | Published |
---|---|---|
20090117156 | GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A - This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS). | 05-07-2009 |
20090130079 | INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES - Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs. | 05-21-2009 |
20100267812 | GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS - This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. | 10-21-2010 |
James Dodge, Framingham, MA US
Patent application number | Description | Published |
---|---|---|
20100173979 | GENE THERAPY FOR LYSOSOMAL STORAGE DISEASES - This disclosure provides methods and compositions for treating lysosomal storage diseases in a subject. In one aspect of the invention, a transgene product is delivered to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. The transgene product may be any that is deficient in a lysosomal storage disease. | 07-08-2010 |
James Dodge, Worcester, MA US
Patent application number | Description | Published |
---|---|---|
20080292593 | GENE THERAPY FOR SPINAL CORD DISORDERS - The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site. | 11-27-2008 |
20090069261 | GENE THERAPY FOR SPINAL CORD DISORDERS - This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector delivers the transgene to a region of the deep cerebellar nuclei region of the brain. Also provided are compositions and methods to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain. | 03-12-2009 |
20090105141 | INTRAVENTRICULAR PROTEIN DELIVERY FOR AMYOTROPHIC LATERAL SCLEROSIS - Amyotrophic Lateral Sclerosis can be successfully treated using intraventricular delivery of a neurotrophic growth factor, IGF-1. The administration can be performed slowly to achieve maximum effect. Effects are seen on both sides of the blood-brain barrier, making this a delivery means for Amyotrophic Lateral Sclerosis which affects both brain and skeletal muscle. | 04-23-2009 |
20090123451 | SLOW INTRAVENTRICULAR DELIVERY - Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain. | 05-14-2009 |
20140356327 | GENE THERAPY FOR SPINAL CORD DISORDERS - The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site. | 12-04-2014 |
James Dodge, Waukesha, WI US
Patent application number | Description | Published |
---|---|---|
20130058545 | METHOD AND APPARATUS FOR DETERMINING A SUBJECTS ORIENTATION - A method for determining a subject's orientation includes receiving, at an imaging system, an input that indicates an orientation of a subject being imaged, automatically determining the orientation of the subject using a feature recognition system, comparing the received input to the automatically determined orientation, and generating an image, the image including orientation indicia based on the comparison. An object orientation recognition system and an imaging system are also described herein. | 03-07-2013 |
James Dodge, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20150151007 | GENE THERAPY FOR LYSOSOMAL STORAGE DISEASES - This disclosure provides methods and compositions for treating lysosomal storage diseases in a subject. In one aspect of the invention, a transgene product is delivered to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. The transgene product may be any that is deficient in a lysosomal storage disease. | 06-04-2015 |